Senzime AB
 | This draft appears to have been generated by a large language model (such as ChatGPT) without having been rigorously scrutinized for verifiability, neutrality, original research, and copyright compliance. It may include misleading or inaccurate claims and fake references that sound plausible. The reason given is: Markdown, one shot creation, red cats (May 2026) (Learn how and when to remove this template message) |
| Public limited company | |
| Traded as | Nasdaq Stockholm: SEZI OTCQX: SNZZF |
| ISIN | 🆔 |
| Industry | Medical devices |
| Founded 📆 | 1999 |
| Founder 👔 | |
| Headquarters 🏙️ | Uppsala, Sweden |
Area served 🗺️ | |
Key people | Philip Siberg (CEO) Per Wold-Olsen (Chairman of the Board) Sorin J. Brull (Chief Medical Officer) |
| Products 📟 | TetraGraph neuromuscular monitor ExSpiron respiratory monitor |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Senzime AB is a Swedish medical device company that develops and markets patient monitoring systems, primarily for use during and after surgery.
History
Senzime was founded in 1999 in Uppsala, Sweden, initially focusing on biosensor technology for continuous analysis of glucose and lactate in medical and biochemical applications.
In 2014, Acacia Designs B.V. was founded in the Netherlands by anesthesiologist Sorin J. Brull and biomedical engineer David R. Hampton to develop an electromyography (EMG)-based neuromuscular monitor.[1] The technology upgraded earlier prototype work presented at the 2012 American Society of Anesthesiologists annual meeting. Brull is the inventor of the core TetraGraph technology [1], and is listed as an inventor on patents related to electromyography-based neuromuscular monitoring systems and disposable electrodes, including foundational work assigned to Acacia Designs B.V. (later acquired by Senzime).[1][2]
On 3 May 2016, Senzime acquired Acacia Designs B.V. in a non-cash share exchange valued at approximately SEK 94 million. Acacia shareholders received 16,076,730 new Senzime shares, resulting in 50% ownership of the post-acquisition company. The acquisition was accompanied by a fully guaranteed rights issue of SEK 15.2 million.[1][3]
The TetraGraph system received CE mark approval in December 2017[3] and U.S. FDA 510(k) clearance in October 2019.[4]
In 2022, Senzime acquired U.S.-based Respiratory Motion, Inc., adding the ExSpiron respiratory volume monitor to its portfolio.[5]
Products
TetraGraph
The TetraGraph is an electromyography (EMG)-based quantitative neuromuscular monitor used to assess the depth of neuromuscular block during general anesthesia. It measures muscle response to electrical nerve stimulation via surface electrodes.[1]
Clinical validation
Multiple peer-reviewed studies have evaluated the TetraGraph's performance against acceleromyography (AMG) and mechanomyography (MMG), the historical laboratory reference standard. A 2021 study in *Anesthesiology* found higher precision and greater repeatability with the TetraGraph EMG than with AMG-based monitors, and concluded that the TetraGraph was a better indicator of adequate recovery from neuromuscular block and readiness for safe tracheal extubation.[6]
A 2021 study in the *Journal of Clinical Anesthesia* compared the TetraGraph directly with the TOFscan in the post-anesthesia care unit and concluded that the two devices provide interchangeable quantitative measurements once the train-of-four (TOF) ratio reaches 0.90 or greater.[7]
A 2025 study validated the TetraGraph across all levels of neuromuscular block (including deep and profound block) against mechanomyography and reported high accuracy and precision.[8] A separate 2024 study in *Anesthesiology* comparing multiple EMG and AMG devices further supported the consistency of EMG-based systems such as the TetraGraph relative to the MMG reference standard.[9]
ExSpiron
The ExSpiron is a non-invasive respiratory volume monitor that uses bioelectrical impedance to measure minute ventilation in spontaneously breathing patients. It was developed by cardiothoracic surgeon Jenny E. Freeman, MD, founder and former CEO of Respiratory Motion, Inc.[10] It was added to Senzime’s portfolio through the 2022 acquisition of Respiratory Motion, Inc.
Clinical validation
The ExSpiron has been evaluated in peer-reviewed studies for accuracy in detecting respiratory depression and monitoring minute ventilation. A 2017 study published in *PLOS ONE* validated the device's ability to quantify respiratory depression during preoperative sedation using impedance-based respiratory volume monitoring.[11] A 2024 validation study in the *Journal of Clinical Monitoring and Computing* further confirmed its performance in healthy volunteers.[12]
Clinical context
Quantitative neuromuscular monitoring is recommended by major anesthesiology societies to reduce the risk of residual neuromuscular block after surgery. The American Society of Anesthesiologists (ASA) 2023 practice guidelines advocate for quantitative monitoring in all patients receiving neuromuscular blocking agents.[13] The 2023 European Society of Anaesthesiology and Intensive Care (ESAIC) guidelines also support these recommendations.[14] Similar endorsements in pediatric patients, including the preference for electromyography (EMG) as the method of monitoring, appear in the 2025 ESAIC and ESPA Guidelines on neuromuscular block in anaesthetised children.[15]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Senzime acquires Acacia Designs". Nordic Life Science News. 4 May 2016. Retrieved 2026-05-24.
- ↑ "Neuromuscular monitoring display system". Google Patents. Retrieved 2026-05-24.
- ↑ 3.0 3.1 "Senzime wins CE Mark for TetraGraph neuromuscular monitor". MassDevice. 12 December 2017. Retrieved 2026-05-24.
- ↑ "510(k) Premarket Notification – TetraGraph Neuromuscular Transmission Monitor". U.S. Food and Drug Administration. 18 October 2019. Retrieved 2026-05-24.
- ↑ "Respiratory Motion – Acquisition". PitchBook. Retrieved 2026-05-24.
- ↑ Nemes, R.; Lengyel, S.; Nagy, G.; et al. (2021). "Ipsilateral and simultaneous comparison of responses from acceleromyography- and electromyography-based neuromuscular monitors". Anesthesiology. 135 (4): 597–611. doi:10.1097/ALN.0000000000003896. PMC 8284665 Check
|pmc=value (help). PMID 34270621 Check|pmid=value (help). - ↑ Renew, J.R.; Hernandez-Torres, V.; Logvinov, I.; et al. (2021). "Comparison of the TetraGraph and TOFscan for monitoring recovery from neuromuscular blockade in the Post Anesthesia Care Unit". Journal of Clinical Anesthesia. 71 (110234). doi:10.1016/j.jclinane.2021.110072 (inactive 24 May 2026).
- ↑ Ebert, T.J.; Vogt, J.A.; Kaur, R.; et al. (2025). "Train-of-four ratio, counts and post-tetanic counts with the TetraGraph electromyograph in comparison to mechanomyography". Journal of Clinical Monitoring and Computing. 39 (1): 149–156. doi:10.1007/s10877-024-01225-3. PMID 39424740 Check
|pmid=value (help). - ↑ Wedemeyer, Z.; Michaelsen, K.E.; Jelacic, S.; et al. (2024). "Accuracy and precision of three acceleromyographs, three electromyographs, and a mechanomyograph measuring the train-of-four ratio in the absence of neuromuscular blocking drugs". Anesthesiology. 141 (2): 262–271. doi:10.1097/ALN.0000000000005051. PMID 38728090 Check
|pmid=value (help). - ↑ "Respiratory Motion, Inc. Receives 510(k) Clearance for ExSpiron™ Monitor". Fierce Healthcare. 11 October 2012. Retrieved 2026-05-24.
- ↑ Gonzalez Castro, L.N. (2017). "Quantification of respiratory depression during pre-operative sedation with midazolam and fentanyl using a non-invasive respiratory volume monitor". PLOS ONE. 12 (3): e0172750. doi:10.1371/journal.pone.0172750. PMC 5325566. PMID 28235069.
- ↑ Gatti, S.; Rezoagli, E.; Madotto, F.; Foti, G.; Bellani, G. (2024). "Validation of ExSpiron®Xi in healthy volunteers". Journal of Clinical Monitoring and Computing. 38 (2): 539–551. doi:10.1007/s10877-023-01107-0. PMC 10994998 Check
|pmc=value (help). PMID 38238635 Check|pmid=value (help). - ↑ Thilen, S.R.; Weigel, W.A.; Todd, M.M.; et al. (1 January 2023). "2023 American Society of Anesthesiologists practice guidelines for monitoring and antagonism of neuromuscular blockade". Anesthesiology. 138 (1): 13–41. doi:10.1097/ALN.0000000000004379. PMID 36520073 Check
|pmid=value (help). - ↑ Fuchs-Buder, T; Romero, C.S.; Lewald, H.; et al. (February 2023). "Peri-operative management of neuromuscular blockade: a guideline from the European Society of Anaesthesiology and Intensive Care". European Journal of Anaesthesiology. 40 (2): 82–94. doi:10.1097/EJA.0000000000001769. hdl:2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/363538. PMID 36377554 Check
|pmid=value (help). - ↑ Veyckemans, F.; Debouche, S.; Kaufmann, J.; et al. (2026). "2025 ESAIC and ESPA Guidelines on neuromuscular block in anaesthetised children: Indications, monitoring and reversal". European Journal of Anaesthesiology. 43 (4): 295–323. doi:10.1097/EJA.0000000000002357. PMID 41766420 Check
|pmid=value (help).
Category:Medical device companies of Sweden Category:Companies listed on Nasdaq Stockholm Category:1999 establishments in Sweden Category:Patient monitoring
This article "Senzime AB" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Senzime AB. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
